Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
KALARIS THERAPEUTICS INC (KLRS)
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
$2.36+16.83%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for KLRS yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Advance TH103 to Phase 3 clinical trials | Kalaris aims to start Phase 3 trials for TH103 soon. | Improving | TH103 does not start Phase 3 trials by end of 2026 | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 5, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Nov 11, 2026
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a speculative clinical-development business, not an established earnings compounder. The long-term thesis is in a watch state: TH103 is progressing, but confidence is low and recent performance remains below its industry cohort.
The snapshot provides no valuation multiple or clear expectations estimate, so it does not support a firm view on whether KLRS is cheap, fair, or expensive versus peers. It reports low valuation fragility, meaning no listed warning signs are concentrating market fragility, but that does not resolve the expectations gap.
Near term, a 47% estimated miss probability and high-risk profile make the next report important, despite an earnings beat in August. Management says TH103 remains on track for preliminary data in the first half of 2027 and Phase 3 initiation by year-end 2027; cash declined from the first to second quarter but is reported to fund operations into Q4 2027. The CFO transition and filed litigation add uncertainty, while the stronger Healthcare sector backdrop is a tailwind rather than proof of company-level progress.
The multi-year thesis depends on TH103 trial progress and whether preliminary data arrive on the stated timeline, alongside continued cash discipline. Near term, a guidance cut or further weakening in jobs data could pressure the business backdrop, while continued strong results and guidance from sector bellwethers could support Healthcare sentiment.
Over the next one to three years, KLRS remains a high-risk, low-confidence clinical story with a defined TH103 milestone path but limited evidence of financial strength. The thesis hinges on clinical progress, cash runway, and the next guidance update. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| A primary condition in KALARIS THERAPEUTICS INC's published investment case. The stated target is Raise at least $100 million by September 2027. |
| Intact |
| Cash raised falls below $100 million by September 2027 |
Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 5, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Manage CFO transition to maintain financial leadership | A supporting condition in KALARIS THERAPEUTICS INC's published investment case. The stated target is Appoint a permanent CFO by end of 2026. | Intact | No permanent CFO appointed by end of 2026 | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 5, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$-1.63 → $-1.65 · observed estimates
$0.01B → $0.01B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $-1.63 | $10,000,000 | 6 / 5 |
| 2026-07-25 | $-1.63 | $10,000,000 | 6 / 5 |
| 2026-07-26 | $-1.63 | $10,000,000 | 6 / 5 |
| 2026-07-27 | $-1.63 | $10,000,000 | 6 / 5 |
| 2026-07-28 | $-1.63 | $10,000,000 | 6 / 5 |
| 2026-07-29 | $-1.63 | $11,428,570 | 8 / 7 |
| 2026-07-30 | $-1.63 | $11,428,570 | 8 / 7 |
| 2026-07-31 | $-1.63 | $11,428,570 | 8 / 7 |
| 2026-08-01 | $-1.63 | $10,000,000 | 6 / 5 |
| 2026-08-02 | $-1.63 | $10,000,000 | 6 / 5 |
| 2026-08-03 | $-1.63 | $11,428,570 | 8 / 7 |
| 2026-08-04 | $-1.63 | $11,428,570 | 8 / 7 |
| 2026-08-05 | $-1.63 | $11,428,570 | 8 / 7 |
| 2026-08-06 | $-1.63 | $10,000,000 | 6 / 5 |
| 2026-08-07 | $-1.63 | $10,000,000 | 6 / 5 |
| 2026-08-08 | $-1.63 | $10,000,000 | 6 / 5 |
| 2026-08-09 | $-1.63 | $10,000,000 | 6 / 5 |
| 2026-08-10 | $-1.63 | $11,428,570 | 8 / 7 |
| 2026-08-12 | $-1.63 | $10,000,000 | 6 / 5 |
| 2026-08-13 | $-1.63 | $11,428,570 | 8 / 7 |
| 2026-08-14 | $-1.63 | $10,000,000 | 6 / 5 |
| 2026-08-15 | $-1.63 | $10,000,000 | 6 / 5 |
| 2026-08-16 | $-1.63 | $10,000,000 | 6 / 5 |
| 2026-08-17 | $-1.63 | $10,000,000 | 6 / 5 |
| 2026-08-18 | $-1.63 | $10,000,000 | 6 / 5 |
| 2026-08-19 | $-1.63 | $10,000,000 | 6 / 5 |
| 2026-08-20 | $-1.66 | $10,000,000 | 6 / 5 |
| 2026-08-21 | $-1.66 | $10,000,000 | 6 / 5 |
| 2026-08-22 | $-1.66 | $10,000,000 | 6 / 5 |
| 2026-08-23 | $-1.66 | $10,000,000 | 6 / 5 |
| 2026-08-24 | $-1.66 | $10,000,000 | 6 / 5 |
| 2026-08-25 | $-1.66 | $10,000,000 | 6 / 5 |
| 2026-08-26 | $-1.66 | $10,000,000 | 6 / 5 |
| 2026-08-27 | $-1.66 | $10,000,000 | 6 / 5 |
| 2026-08-28 | $-1.66 | $10,000,000 | 6 / 5 |
| 2026-08-29 | $-1.66 | $10,000,000 | 6 / 5 |
| 2026-08-30 | $-1.66 | $10,000,000 | 6 / 5 |
| 2026-08-31 | $-1.66 | $10,000,000 | 6 / 5 |
| 2026-09-01 | $-1.66 | $10,000,000 | 6 / 5 |
| 2026-09-02 | $-1.66 | $10,000,000 | 6 / 5 |
| 2026-09-03 | $-1.66 | $10,000,000 | 6 / 5 |
| 2026-09-04 | $-1.66 | $10,000,000 | 6 / 5 |
| 2026-09-05 | $-1.66 | $10,000,000 | 6 / 5 |
| 2026-09-06 | $-1.66 | $10,000,000 | 6 / 5 |
| 2026-09-07 | $-1.66 | $10,000,000 | 6 / 5 |
| 2026-09-08 | $-1.66 | $10,000,000 | 6 / 5 |
| 2026-09-09 | $-1.66 | $10,000,000 | 6 / 5 |
| 2026-09-10 | $-1.66 | $10,000,000 | 6 / 5 |
| 2026-09-11 | $-1.66 | $10,000,000 | 6 / 5 |
| 2026-09-12 | $-1.66 | $10,000,000 | 6 / 5 |
| 2026-09-13 | $-1.66 | $10,000,000 | 6 / 5 |
| 2026-09-14 | $-1.66 | $10,000,000 | 6 / 5 |
| 2026-09-15 | $-1.66 | $10,000,000 | 6 / 5 |
| 2026-09-16 | $-1.66 | $10,000,000 | 6 / 5 |
| 2026-09-17 | $-1.66 | $10,000,000 | 6 / 5 |
| 2026-09-18 | $-1.66 | $10,000,000 | 6 / 5 |
| 2026-09-19 | $-1.66 | $10,000,000 | 6 / 5 |
| 2026-09-20 | $-1.66 | $10,000,000 | 6 / 5 |
| 2026-09-21 | $-1.66 | $10,000,000 | 6 / 5 |
| 2026-09-22 | $-1.66 | $10,000,000 | 6 / 5 |
| 2026-09-23 | $-1.66 | $10,000,000 | 6 / 5 |
| 2026-09-24 | $-1.66 | $10,000,000 | 6 / 5 |
| 2026-09-25 | $-1.66 | $10,000,000 | 6 / 5 |
| 2026-09-26 | $-1.66 | $10,000,000 | 6 / 5 |
| 2026-09-27 | $-1.66 | $10,000,000 | 6 / 5 |
| 2026-09-28 | $-1.66 | $10,000,000 | 6 / 5 |
| 2026-09-29 | $-1.66 | $10,000,000 | 6 / 5 |
| 2026-09-30 | $-1.66 | $10,000,000 | 6 / 5 |
| 2026-10-01 | $-1.66 | $10,000,000 | 6 / 5 |
| 2026-10-02 | $-1.66 | $10,000,000 | 6 / 5 |
| 2026-10-03 | $-1.66 | $10,000,000 | 6 / 5 |
| 2026-10-04 | $-1.66 | $10,000,000 | 6 / 5 |
| 2026-10-05 | $-1.66 | $10,000,000 | 6 / 5 |
| 2026-10-06 | $-1.66 | $10,000,000 | 6 / 5 |
| 2026-10-07 | $-1.66 | $10,000,000 | 6 / 5 |
| 2026-10-08 | $-1.66 | $10,000,000 | 6 / 5 |
| 2026-10-09 | $-1.66 | $10,000,000 | 6 / 5 |
| 2026-10-10 | $-1.65 | $10,000,000 | 6 / 5 |
| 2026-10-11 | $-1.65 | $10,000,000 | 6 / 5 |
| 2026-10-12 | $-1.65 | $10,000,000 | 6 / 5 |
| 2026-10-13 | $-1.65 | $10,000,000 | 6 / 5 |
| 2026-10-14 | $-1.65 | $10,000,000 | 6 / 5 |
| 2026-10-15 | $-1.65 | $10,000,000 | 6 / 5 |
| 2026-10-16 | $-1.65 | $10,000,000 | 6 / 5 |
| 2026-10-17 | $-1.65 | $10,000,000 | 6 / 5 |
| 2026-10-18 | $-1.65 | $10,000,000 | 6 / 5 |
| 2026-10-19 | $-1.65 | $10,000,000 | 6 / 5 |
| 2026-10-20 | $-1.65 | $10,000,000 | 6 / 5 |
| 2026-10-21 | $-1.65 | $10,000,000 | 6 / 5 |
| 2026-10-22 | $-1.65 | $10,000,000 | 6 / 5 |
| 2026-10-23 | $-1.65 | $10,000,000 | 6 / 5 |
| 2026-10-24 | $-1.65 | $10,000,000 | 6 / 5 |
| 2026-10-25 | $-1.65 | $10,000,000 | 6 / 5 |
| 2026-10-26 | $-1.65 | $10,000,000 | 6 / 5 |
| 2026-10-27 | $-1.65 | $10,000,000 | 6 / 5 |
| 2026-10-28 | $-1.65 | $10,000,000 | 6 / 5 |
| 2026-10-29 | $-1.65 | $10,000,000 | 6 / 5 |
| 2026-10-30 | $-1.65 | $10,000,000 | 6 / 5 |
| 2026-10-31 | $-1.65 | $10,000,000 | 6 / 5 |
| 2026-11-01 | $-1.65 | $10,000,000 | 6 / 5 |
| 2026-11-02 | $-1.65 | $10,000,000 | 6 / 5 |
| 2026-11-03 | $-1.65 | $10,000,000 | 6 / 5 |
| 2026-11-04 | $-1.65 | $10,000,000 | 6 / 5 |
| 2026-11-05 | $-1.65 | $10,000,000 | 6 / 5 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 7 Buy / Strong Buy · 1 Hold · 0 Sell / Strong Sell
Recent actions · Oct 7–Nov 5 · 0 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 7, 2026–Nov 5, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.